| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 25 | 2024 | 619 | 5.990 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 22 | 2024 | 1187 | 3.300 |
Why?
|
| Gastrointestinal Microbiome | 11 | 2025 | 824 | 2.550 |
Why?
|
| Dysbiosis | 5 | 2025 | 145 | 1.130 |
Why?
|
| Bacteroides | 2 | 2024 | 37 | 1.080 |
Why?
|
| Thrombospondins | 2 | 2018 | 14 | 0.720 |
Why?
|
| Metabolome | 2 | 2025 | 312 | 0.650 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2025 | 149 | 0.630 |
Why?
|
| Gastrointestinal Diseases | 1 | 2023 | 361 | 0.630 |
Why?
|
| Stem Cells | 4 | 2024 | 753 | 0.600 |
Why?
|
| Paneth Cells | 1 | 2017 | 26 | 0.560 |
Why?
|
| Stem Cell Niche | 1 | 2017 | 58 | 0.520 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 292 | 0.520 |
Why?
|
| Transplantation, Homologous | 8 | 2024 | 690 | 0.500 |
Why?
|
| Intestines | 2 | 2017 | 615 | 0.490 |
Why?
|
| Smooth Muscle Tumor | 1 | 2014 | 3 | 0.440 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2014 | 31 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1354 | 0.430 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 23 | 0.430 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 44 | 0.420 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 169 | 0.420 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 80 | 0.420 |
Why?
|
| Animals | 20 | 2025 | 36524 | 0.410 |
Why?
|
| Vincristine | 1 | 2014 | 196 | 0.410 |
Why?
|
| Mice | 17 | 2025 | 19030 | 0.400 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 92 | 0.390 |
Why?
|
| Vaginal Neoplasms | 1 | 2012 | 19 | 0.380 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 306 | 0.370 |
Why?
|
| Neutropenia | 2 | 2022 | 204 | 0.350 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2010 | 2 | 0.350 |
Why?
|
| Histiocytic Sarcoma | 1 | 2010 | 4 | 0.350 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 703 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2010 | 64 | 0.340 |
Why?
|
| Colitis | 2 | 2023 | 173 | 0.340 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 447 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2010 | 102 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 4 | 2025 | 2573 | 0.330 |
Why?
|
| Neoplasms | 2 | 2022 | 3030 | 0.320 |
Why?
|
| HSP47 Heat-Shock Proteins | 2 | 2019 | 4 | 0.300 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 331 | 0.300 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 363 | 0.300 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 300 | 0.290 |
Why?
|
| Humans | 29 | 2025 | 134032 | 0.250 |
Why?
|
| Mucus | 2 | 2022 | 39 | 0.250 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 1814 | 0.250 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 815 | 0.240 |
Why?
|
| Mucins | 2 | 2022 | 77 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 3 | 2024 | 1083 | 0.240 |
Why?
|
| Middle Aged | 15 | 2025 | 29393 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 294 | 0.230 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 9 | 0.230 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 4867 | 0.230 |
Why?
|
| Bile Ducts | 1 | 2024 | 54 | 0.220 |
Why?
|
| Immunological Synapses | 1 | 2024 | 29 | 0.220 |
Why?
|
| Female | 21 | 2025 | 71818 | 0.220 |
Why?
|
| Feces | 2 | 2024 | 788 | 0.210 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 1416 | 0.200 |
Why?
|
| Xylose | 1 | 2022 | 9 | 0.200 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2023 | 106 | 0.200 |
Why?
|
| Carbapenems | 1 | 2022 | 43 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 1408 | 0.190 |
Why?
|
| Biopsy | 2 | 2023 | 1303 | 0.180 |
Why?
|
| Stomach | 1 | 2024 | 271 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 486 | 0.180 |
Why?
|
| Polysaccharides | 1 | 2022 | 150 | 0.180 |
Why?
|
| Fatal Outcome | 2 | 2014 | 376 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 149 | 0.180 |
Why?
|
| Organoids | 1 | 2024 | 299 | 0.180 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 2 | 0.180 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2021 | 2 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 2 | 2015 | 620 | 0.180 |
Why?
|
| Vitamin A | 2 | 2019 | 61 | 0.180 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2020 | 244 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 894 | 0.170 |
Why?
|
| Filgrastim | 1 | 2020 | 13 | 0.170 |
Why?
|
| Methylamines | 1 | 2020 | 20 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 26 | 0.170 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 34 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 503 | 0.170 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 425 | 0.170 |
Why?
|
| Ileal Diseases | 1 | 2020 | 28 | 0.160 |
Why?
|
| Duodenal Diseases | 1 | 2020 | 34 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1310 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 128 | 0.160 |
Why?
|
| Leukemia | 1 | 2023 | 379 | 0.160 |
Why?
|
| Ileum | 1 | 2020 | 136 | 0.160 |
Why?
|
| Interleukin-17 | 2 | 2022 | 130 | 0.160 |
Why?
|
| Duodenum | 1 | 2020 | 110 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 719 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2018 | 250 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 255 | 0.150 |
Why?
|
| Japan | 2 | 2018 | 155 | 0.150 |
Why?
|
| Endothelium, Lymphatic | 1 | 2018 | 10 | 0.150 |
Why?
|
| Adult | 10 | 2024 | 31958 | 0.150 |
Why?
|
| Macrophages | 2 | 2020 | 703 | 0.150 |
Why?
|
| WT1 Proteins | 1 | 2018 | 27 | 0.150 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2018 | 14 | 0.150 |
Why?
|
| Skin Physiological Phenomena | 1 | 2018 | 19 | 0.140 |
Why?
|
| Cecum | 1 | 2018 | 28 | 0.140 |
Why?
|
| alpha-Defensins | 1 | 2017 | 6 | 0.140 |
Why?
|
| Cytoprotection | 1 | 2017 | 39 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4801 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1720 | 0.140 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 87 | 0.140 |
Why?
|
| Metabolomics | 1 | 2021 | 458 | 0.140 |
Why?
|
| Male | 14 | 2025 | 66022 | 0.140 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 46 | 0.140 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 151 | 0.140 |
Why?
|
| Aged | 10 | 2025 | 21750 | 0.130 |
Why?
|
| Lymphoma | 1 | 2020 | 335 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2017 | 253 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2018 | 135 | 0.130 |
Why?
|
| Remission Induction | 2 | 2018 | 310 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1535 | 0.120 |
Why?
|
| Young Adult | 5 | 2018 | 9912 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 229 | 0.120 |
Why?
|
| Microbiota | 1 | 2021 | 445 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2018 | 249 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2017 | 727 | 0.120 |
Why?
|
| Dry Eye Syndromes | 1 | 2019 | 280 | 0.120 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 40 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2018 | 329 | 0.120 |
Why?
|
| Mannans | 1 | 2015 | 15 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 217 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2018 | 544 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 63 | 0.110 |
Why?
|
| Spinal Neoplasms | 1 | 2015 | 75 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2015 | 148 | 0.110 |
Why?
|
| Th17 Cells | 1 | 2015 | 101 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 1440 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 48 | 0.110 |
Why?
|
| Allografts | 3 | 2020 | 198 | 0.110 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 80 | 0.110 |
Why?
|
| Bacteria | 1 | 2017 | 538 | 0.100 |
Why?
|
| Isoantibodies | 1 | 2013 | 72 | 0.100 |
Why?
|
| Homeostasis | 1 | 2018 | 750 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2018 | 1004 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 237 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 288 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 609 | 0.100 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 485 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5475 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2014 | 302 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 567 | 0.100 |
Why?
|
| Prognosis | 3 | 2018 | 5081 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2014 | 563 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2015 | 1597 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2015 | 403 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1388 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2020 | 17507 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1764 | 0.080 |
Why?
|
| Tacrolimus | 2 | 2022 | 108 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2013 | 523 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 671 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2017 | 2041 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2936 | 0.080 |
Why?
|
| Cyclosporine | 2 | 2019 | 148 | 0.070 |
Why?
|
| Mutation | 2 | 2021 | 6304 | 0.070 |
Why?
|
| Survival Rate | 3 | 2018 | 2218 | 0.070 |
Why?
|
| Liposomes | 2 | 2019 | 207 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 558 | 0.070 |
Why?
|
| Fibrosis | 2 | 2019 | 463 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2023 | 1255 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2195 | 0.060 |
Why?
|
| Dioxoles | 1 | 2024 | 11 | 0.060 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2024 | 24 | 0.060 |
Why?
|
| NFATC Transcription Factors | 1 | 2024 | 48 | 0.050 |
Why?
|
| Benzamides | 1 | 2024 | 125 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2024 | 133 | 0.050 |
Why?
|
| Human papillomavirus 16 | 1 | 2024 | 100 | 0.050 |
Why?
|
| Gene Library | 1 | 2024 | 225 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 15 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 33 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 60 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3853 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2023 | 181 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 407 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2023 | 513 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 358 | 0.050 |
Why?
|
| Time Factors | 1 | 2012 | 6604 | 0.050 |
Why?
|
| Colony-Stimulating Factors | 1 | 2021 | 3 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2022 | 4006 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 20581 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 672 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 937 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2020 | 107 | 0.040 |
Why?
|
| Atrophy | 1 | 2020 | 251 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1471 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2019 | 143 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 29 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 961 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 101 | 0.040 |
Why?
|
| Hair Follicle | 1 | 2018 | 35 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2017 | 21 | 0.040 |
Why?
|
| Histocompatibility | 1 | 2017 | 50 | 0.040 |
Why?
|
| Lacrimal Apparatus | 1 | 2019 | 120 | 0.040 |
Why?
|
| Antilymphocyte Serum | 1 | 2017 | 56 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2018 | 79 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2023 | 746 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 125 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 820 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 155 | 0.030 |
Why?
|
| Epithelium | 1 | 2018 | 366 | 0.030 |
Why?
|
| Liver | 1 | 2024 | 1880 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 270 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 328 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3781 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 972 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2012 | 13050 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 315 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 342 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1193 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1315 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 417 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 922 | 0.030 |
Why?
|
| Candida albicans | 1 | 2015 | 90 | 0.030 |
Why?
|
| Candidiasis | 1 | 2015 | 139 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 11162 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 545 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 724 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 1140 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2015 | 538 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 837 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2299 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1331 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1919 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6601 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3181 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2910 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7207 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4927 | 0.020 |
Why?
|